RxDoctor Payments Data

Anne Montgomery, MD

Internal Medicine · Fayetteville, ARNPI 1922452689

Payments from drug & device makers

$336in general payments, 2019–2025

Across 18 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$73
  • Novo Nordisk$70
  • GSK$46
  • Mylan Specialty L.p.$42
  • AstraZeneca$38
  • Exact Sciences$21
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$336 in reported general payments places this provider in the 55th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$39,181
Medicare patients
166
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$63,346
MounjaroTirzepatide33$33,147
EliquisApixaban37$30,234
TrulicityDulaglutide24$24,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,189
JardianceEmpagliflozin11$10,089
FarxigaDapagliflozin Propanediol11$9,115
Incruse ElliptaUmeclidinium Bromide13$8,679
Breo ElliptaFluticasone/Vilanterol15$8,410
Tresiba Flextouch U-100Insulin Degludec12$7,887
Pregabalin99$7,535
EntrestoSacubitril/Valsartan11$7,467
Novolog FlexpenInsulin Aspart15$2,293
Celecoxib55$1,829
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$1,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$70$63,34664 claims
Lilly USA, LLCMounjaro, Trulicity$13$57,21357 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$46$32,27842 claims
PfizerEliquis$19$30,23437 claims
AstraZenecaFarxiga$38$9,11511 claims
AbbVieSynthroid$73$1,13219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →